Latest Updates

A new peer-reviewed study in Acta Paediatr finds GLP-1 drugs like liraglutide and semaglutide meaningfully change body composition in teens with obesity.

A large Scandinavian study found GLP-1 receptor agonists like Ozempic may be linked to a lower risk of developing Parkinson's disease. Here's what we know.

A phase 3a trial published in Lancet Diabetes & Endocrinology found cagrilintide plus semaglutide outperformed semaglutide alone for weight loss in Japan and Taiwan.

A new peer-reviewed case study in the Journal of Bone and Mineral Research raises important questions about GLP-1 drugs like semaglutide and bone density loss.

A new peer-reviewed review in Advances in Therapeutics explores how GLP-1 drugs like Ozempic could benefit people with cystic fibrosis and related diabetes.

A new peer-reviewed study explores how tirzepatide, the drug in Mounjaro and Zepbound, may lower blood pressure and support cardiac function in a rat model.

A new peer-reviewed review finds liraglutide, semaglutide, and tirzepatide may slow or reverse prediabetes progression — here's what it means for patients.

A new peer-reviewed rat study finds repeated semaglutide treatment reduced cocaine-seeking behavior, raising hope for future addiction treatment research.

A new real-world registry study examines how semaglutide and SGLT2 inhibitors affect outcomes in type 2 diabetes patients after acute coronary syndrome.

New research links the absorption enhancer in oral semaglutide (Rybelsus) to gut microbiome disruption and inflammation. Here's what patients should know.

A new real-world study in Transplantation journal examines how kidney transplant recipients tolerate and respond to tirzepatide (Mounjaro/Zepbound).

A new case report in ACG Case Reports Journal finds semaglutide helped a woman with ulcerative colitis achieve remission. Here's what patients should know.

A new peer-reviewed study in BJGP Open reveals how German primary care doctors experience prescribing GLP-1 medications like semaglutide in real-world practice.

A pilot study from the SLIM LIVER trial found semaglutide may slow epigenetic aging in people with HIV and liver disease. Here's what it means for patients.

A pilot study from the SLIM LIVER trial found semaglutide may slow epigenetic aging in people with HIV and metabolic liver disease. Here's what the findings mean.